← Browse by Condition
Medical Condition

refractory indolent non hodgkin lymphoma

Total Trials
1
Recruiting Now
1
Trial Phases
Phase 1
NCT07166419 Phase 1
Recruiting

Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia

Enrollment
24 pts
Location
United States
Sponsor
Ohio State University Comprehe...
View Trial →